Introduction
Glycan chains were selected by nature as the best molecules for decorating the surfaces of all cells [1] . These chains participate in various processes, including subcellular and cellular trafficking, intercellular adhesion, signalling and microbial attachment [1, 2] . The sugar moieties that modify proteins and lipids play crucial roles in determining their structure, function, activity and immunogenicity [3] .
Different cell types in each organism express a distinct configuration of glycans under defined conditions. Although these glycan expression patterns are mostly conserved within the same species, it is possible to find some intraspecies variations (e.g., ABO blood groups within humans and other primates). Interspecies variations are much more extensive, and in rare cases, a specific type of terminal glycan can be permanently eliminated from an entire evolutionary clade [4] . The human-specific loss of one type of sialic acid, N-glycolylneuraminic acid, that is common in mammals [5] and the loss of the terminal α-1,3-galactose in Old World primates [6] are two of these extraordinary cases. This review will discuss the consequences, advantages and applications of these eliminated sugars in biological and medical chemistry.
Sialic acids (Sias) are usually found at the terminal positions of the cell surface and secreted glycan molecules of vertebrates, higher invertebrates and some microorganisms. Sias are acidic sugars that belong to a large family of neuraminic acid derivatives. A nine-carbon backbone forms the structural basis of Sias [2, 7] . Sias are hydrophilic and negatively charged at physiological pH, and these features are important for their functions [7] . Sias act as a biological mask to cover the recognition sites of molecules and contribute to the acceptance of cells by the immune system. Some pathogenic microorganisms express Sias on their surface as a means to escape recognition by the host immune system. Sias provide biological recognition sites for hormones, lectins, antibodies and inorganic cations as well as for many pathogens. Sias are implicated in the regulation of embryogenesis and neuronal growth and function [2] , the prevention of unwanted interactions between cells in blood circulation [7] and the determination of the half-life of circulating glycoproteins [8] . The sialylated forms of IgG antibodies have anti-inflammatory activities [9] . Changes in sialic acid expression are signs of various pathological processes, including cancer. One example is the typically high expression of dietary N-glycolylneuraminic acid in several human tumours [1, 10] .
Galactose (Gal) is another widely distributed sugar that is found in glycoproteins and glycolipids and is usually located in the terminal or sub-terminal position. The Gal molecule preferentially assumes a hexopyranose structure and has a specific axial 4-OH group distinguishing it from glucose and other hexoses [11] . This hydroxyl group is responsible for the phase transition behaviour and intramolecular hydrogen bond formation of Gal, which contribute to the recognition and binding properties of this sugar [12] . Gal bound by an α-1,3-linkage is the terminal saccharide of the glycan chain that forms the α-gal epitope (Galα1-3Galβ1-4GlcNAc-R), an epitope that is abundantly expressed on the glycoconjugates of nonprimate mammals, prosimians and New World monkeys. However, this epitope is missing in humans, apes and Old World monkeys, which instead produce anti-Gal antibodies. The exact function of the α-gal epitope, except for its role as a receptor for certain pathogens, is largely unknown [13] .
Although sialylation and α-1,3-galactosylation are distinct processes, they have several features in common. These sugars are both involved in nutritional complications arising from evolution, and their formations are both the center of attention as processes with potential biotechnological application. Sialylation could have implications in cancer immunotherapy, the treatment of autoimmune diseases and the improvement of the pharmacokinetic properties of protein therapeutics. Additionaly, α-1,3-galactosylation is a promising tool for cancer immunotherapy and for increasing the immunogenicity of microbial vaccines.
Sialylation, α-1,3-galactosylation and evolution
Glycans on the cell surface, as previously mentioned, are important for the biological processes of hosts and also for the binding of pathogens. Therefore, glycans are part of never-ending cycles of evolutionary Red Queen effects, according to which the host must evade the more rapidly developing pathogens that infect them by changing their glycan expression patterns without endangering their own survival [4, 14, 15] . Glycans can change dynamically, which is the reason they are found naturally in many structural variations. This dynamic nature contributes to biological diversity and, perhaps, even to speciation [4] .
Sias are the major cell-surface molecules of deuterostome organisms (vertebrates and higher invertebrates). Sias achieved this primacy during the Cambrian expansion approximately 530 million years ago. Since then, Sias have become highly diversified, and now it is possible to find more than 50 structural variations in nature [5] . The two most prevalent types of Sias on mammalian cells are N-glycolylneuraminic acid (Neu5Gc) and N-acetylneuraminic acid (Neu5Ac). Humans provide the one exception to the pattern of Sia prevalence observed in mammalian cells [16, 17] .
In human ancestors just before the emergence of the genus Homo (~2-3 mya), a deletion occurred in the gene encoding enzyme cytidine monophosphate N-acetylneuraminic acid hydroxylase (CMAH) [1, 17] , which is located on human chromosome 6 [18] . This deletion was mediated by the transposable element Alu and affected a 92-base pair exon required for enzymatic activity. As a result, the biosynthesis of Neu5Gc was eliminated, whereas its precursor, Neu5Ac, accumulated. The mutated allele is now universal in humans ( Figure 1 ) [1] . The stimulus for the loss of Neu5Gc was most likely a pathogen that bound this sugar. Varki and Gagneux [17] proposed the malaria parasite Plasmodium as a candidate for this pathogen. Interestingly, P. reichenowi, which infects chimpanzees and gorillas, shows a preference for Neu5Gc. This pathogen is the closest relative of P. falciparum, a pathogen of humans that binds to Neu5Ac. P. reichenowi does not infect humans, and vice versa, P. falciparum does not infect chimpanzees. The mutation of CMAH enabled our Homo ancestors to escape a common Plasmodium ancestor that prefers Neu5Gc. P. falciparum most likely arose later when a strain of malaria that infected nonhuman hominids evolved to bind preferentially to the Neu5Ac-rich erythrocytes of our ancestors [17] .
The elimination of Neu5Gc also caused the loss of the preferred ligand for some Sia-binding proteins, e.g., Siglecs. One subclass, known as CD33-related Siglecs (CD33rSiglecs), recognises Sias as "self" and, thus, inhibits the immune response. Because no pathogen has been observed to synthesise Neu5Gc while many can synthesise Neu5Ac, hominid Siglecs preferentially recognise Neu5Gc. The loss of the self ligand for CD33rSiglecs resulted in a hyperimmune state that was most likely temporarily advantageous. Shortly thereafter, this selection favoured amino acid changes allowing CD33rSiglecs to bind Neu5Ac, thereby restoring their inhibitory function [1] . It has also been observed that most humans have varying levels of circulating anti-Neu5Gc antibodies ( Figure 1 ) [7] .
Another interesting human specificity concerning sialic acids is the prevalence of α-2,6-linked Sias in their upper airways. In the upper airways of non-human hominids however, low expression of α-2,6-linked Sias was detected, instead showing a prevalence of α-2,3-linked Sias similar to that found in mice and birds [19] . This difference results in distinct susceptibilities to influenza viruses. The human influenza virus does not cause severe infections in chimpanzees because it prefers α-2,6-linked Sia as a ligand, whereas the avian influenza virus preferentially recognises α-2,3-linked Sia [7] . This α-2,6-linked-Sia-enrichment in human upper airways is caused by the up-regulation of the enzyme ST6Gal-I [20] . Varki [1] suggests that malarial parasites that prefer α-2,3-linked Sias could have been the selective force for the up-regulation of α-2,6-linked Sias on ancestral hominin erythrocytes and secondarily also in other tissues.
Neu5Gc is not the only sugar that "disappeared" in human evolution. Less than 28 mya, shortly before the divergence of apes and monkeys, human ancestors Figure 1 . Elimination of N-glycolylneuraminate (NeuGc) in humans. Human CMP-NeuAc hydroxylase pseudogene is located on chromosome 6 (www.ncbi.nlm.nih.gov). In contrast to all other mammals that contain functional gene, translated protein in humans lacks 104 aminoacids at N-terminus (comparison of aminoacid sequences, blast.ncbi.nlm.nih.gov), thus the enzyme is inactive. For this reason, the biosynthesis of NeuGc from NeuAc has been disabled (chemical equation), resulting in accumulation of CMP-NeuAc. As a consequence, human immune system recognizes NeuGc as foreign, therefore produces antibodies to this sugar, including antibodies specific for N-glycolyl GM3 (structure of murine monoclonal antibody Fab 14F7, www.pdb.org, ID 1RIH). These antibodies show no cross-reactivity to NeuAc. This makes the N-glycolyl GM3 (αNeuGc(2-3)βDGalp(1-4)βDGlcp(1-1)Cer), that is abundantly expressed on tumour cells, a powerful target for cancer immunotherapy.
lost the α-gal epitope. This elimination affected only Old World monkeys, apes and humans because α-gal is still abundantly expressed on surfaces of all other mammalian cells, including those of prosimians and New World monkeys [21] . The synthesis of the α-gal epitope is governed by α-1,3-galactosyltransferase (α1,3GalT) [13, 22] . This enzyme is found only in mammals and not in other vertebrates, which suggests that it appeared at a recent stage of vertebrate evolution. The inactivation of α1,3GalT is responsible for the elimination of α-gal [13] . The human genome contains two homologues of genes encoding α1,3GalT. One α1,3GalT pseudogene is located on chromosome 9 and contains two point deletions that result in a frameshift and a premature stop codon [23] . Another α1,3GalT pseudogene was found on chromosome 12 and contains several deletions. This pseudogene appears to be the result of the conversion of the α1,3GalT mRNA into cDNA, which was subsequently inserted into the chromosome [24] . In addition to α1,3GalT, human chromosome 1 carries a pseudogene for isogloboside 3 synthase (iGb3S), which is an enzyme responsible for the synthesis of isogloboside 3 (iGb3), a glycolipid containing a terminal Galα1-3Gal. It was recently shown that iGb3 activates human natural killer T cells (Figure 2) [25] .
The elimination of α-gal in ancestral Old World primates most likely occurred in response to a pathogen, similar to Neu5Gc elimination. Macher and Galili [13] suggest two possible explanations. A virus, bacterium or protozoan that infected monkeys and apes could have expressed the α-gal epitope or an immunologically cross-reactive carbohydrate structure. The inactivation of α1,3GalT caused immune intolerance to the α-gal epitope, enabling the production of anti-Gal antibodies Figure 2 . Elimination of the α-gal epitope in humans. Human genome carries three α-1,3-galacotsyltransferase pseudogenes on chromosome 9, 12 and 1, respectively (www.ncbi.nlm.nih.gov). Therefore humans, along with apes and Old World monkeys do not produce any active enzyme possessing α-1,3-galactosyltransferase activity. This resulted in elimination of α-gal epitope that is abundantly expressed in all other mammals. Sequences in the picture represent the comparison of catalytic domain aminoacid sequences of human α-1,3-galactosyltransferase, encoded by pseudogene on chromosome 9, with bovine enzyme (blast.ncbi.nlm.nih.gov). Below is a structure of bovine α-1,3-galactosyltransferase catalytic domain (www.pdb.org, ID 1FG5) and the structure of its remnant present in humans (green). As a consequence, human immune system recognizes α-gal epitope (terminal Galα(1,3)Gal) as a foreign, therefore produces anti-Gal immunoglobulins (depicted as general IgG structure on the left, www.pdb.org, ID 1IGY) capable to mediate complement lysis. Also human natural T-cells can be activated by iGB3
This provides a xenotransplantation barrier, but can be beneficial for cancer immunotherapy. against this pathogen. Alternatively, α-gal could have been used by a pathogen as a cellular receptor, and its elimination resulted in resistance to that pathogen [13] . One example is enterotoxin A of Clostridium difficile, which primarily binds to α-gal on intestinal cells [13, 26] .
The evolutionary suppression of α1,3GalT in Old World monkeys, apes and humans led to the production of large amounts of a natural anti-Gal antibody as a result of continuous antigenic stimulation by the carbohydrate antigens of the normal microflora in the gastrointestinal tract. Anti-Gal antibody titres are among the highest in humans (~1% of circulating IgG), and more than 1% of circulating B lymphocytes can produce them. These antibodies typically appear within the first 6 months of life [27] . In addition to the IgG antibodies, IgA anti-Gal antibodies have been identified in body secretions such as saliva, milk and colostrum [28] . In sera of some patients there have also been found anti-Gal IgE antibodies, the impact of which will be discussed later. Anti-Gal antibodies provide an immunological barrier between humans and mammals that produce α-gal, which is clinically important for xenotransplantation. After the transplantation of pig organs into humans, the binding of human anti-Gal antibodies to the abundant α-gal epitopes causes the rejection of the xenograft. This rejection is a consequence of antibody-dependent cell-mediated cytolysis (ADCC), in which anti-Gal antibodies bind to α-gal to direct the subsequent binding of macrophages and NK cells, and anti-Gal-activated complement-mediated cytolysis ( Figure 2) [13, 29] . AntiGal activity increases shortly after xenotransplantation, despite immunosuppressive treatment [30] .
Sialylation, α-1,3-galactosylation and nutrition
Several million years ago, the loss of Neu5Gc and α-gal helped humans to escape pathogens and, thus, survive selection pressures. However, these events also have consequences associated with foods of mammalian origin.
As mentioned above, humans are the only mammals that are not able to synthesise Neu5Gc. However, it is possible to find variable amounts of Neu5Gc on human tissues, especially on cancer and foetal cells, indicating that the sugar must come from external sources [1] . Because plants do not contain any Sias and microorganisms do not synthesise Neu5Gc, the major source seems to be red meat (i.e., lamb, pork and beef) and, to a lesser extent, milk products [31] . Glycosidically bound Neu5Gc enters the cell through macropinocytosis, resulting in pinocytic vesicles and endosomes that are delivered to the lysosome. The lysosomal sialidase then releases Neu5Gc, which is exported to the cytosol by a sialic acid transporter [32] . Neu5Gc in the cytosol is a molecular "Trojan horse", because it is handled by biochemical pathways as if it were the native Neu5Ac. However, the incorporated Neu5Gc is foreign to the immune system [1] . Anti-Neu5Gc antibodies have been demonstrated to circulate in all normal humans, including complement-fixing IgG antibodies that are able to activate and/or kill cells that express Neu5Gc [33] .
Varki [1] suggests that dietary Neu5Gc on cell surfaces interacts with anti-Neu5Gc, thus contributing to some diseases by stimulating chronic inflammation. Dietary Neu5Gc particularly accumulates in the epithelial cells that line hollow organs or in the endothelium that lines blood vessels. The accumulation of Neu5Gc in epithelial cells implies a role in carcinoma development. Despite the production of anti-Neu5Gc antibodies, the immune reaction is insufficient to kill tumours. On the contrary, the antibody-mediated inflammation stimulates tumour growth by recruiting inflammatory cells, which stimulate angiogenesis and provide growth factors [34] . The accumulation of Neu5Gc in the blood vessel endothelium is associated with atherosclerosis. In human atherosclerotic lesions, Neu5Gc is concentrated not just in the overlying endothelium but also inside the plaque [35] . This concentration of Neu5Gc may stimulate the production of anti-Neu5Gc antibodies, thus aggravating chronic inflammation in the progression of atherosclerosis. This finding might explain the results of many epidemiological studies that show an association of red meat ingestion with an increased risk for various diseases [1] .
Additionally, dietary Neu5Gc on the cell surface may provide a ligand for some pathogens. Because these molecules are rare on the cells of normal human tissues, the typical low-affinity, high-avidity binding of pathogens to glycans is not dangerous for humans. A different situation might occur in the presence of a multivalent toxin with relatively high affinity (e.g., the SubAB toxin produced by Escherichia coli that is usually found in cows). The epithelial and endothelial cellular uptake of dietary Neu5Gc followed by exposure to meat or milk products contaminated with SubAB toxin might enable the binding of the toxin to the gut epithelium and its entrance into the bloodstream, thus targeting the kidney endothelium and causing haemolytic-uremic syndrome [36] .
The loss of the α-gal epitope also has some unpleasant consequences in the area of nutrition, although these consequences are of less clinical significance than the loss of Neu5Gc. Carbohydrate moieties in food are often able to induce the production of IgE antibodies. IgE antibodies specific for α-gal are responsible for the red meat allergy. This novel form of food allergy is rare, but it can elicit serious, even fatal, reactions. Patients report anaphylaxis, angioedema or urticaria 3 to 6 hours after eating red meat (i.e., pork, beef and lamb) [37] . The appearance of this allergic reaction is rather endemic, suggesting the presence of a stimulus. Commins et al. [38] presented evidence that tick bites are possibly the only cause of anti-Gal IgE antibody production. A correlation between tick bites and IgE antibodies specific for α-gal was observed in the United States, Australia [38] and Europe [39] . These anti-Gal IgE antibodies are specific not only to red meat but also to cow's milk, which might explain the previously reported sensitivity to beef in children allergic to cow's milk. However, many individuals with α-gal IgE antibodies do not experience reactions after eating red meat [38] .
Outside of the field of nutrition, IgE antibodies specific for α-gal also react with some cat and dog antigens. It has been shown that α-gal is a major IgEbinding epitope on cat IgA, a newly identified cat allergen (Fel d 5), and that this allergic reaction is induced by some parasites [40, 41] . Similarly, patients with α-gal-binding IgE showed hypersensitivity and/or anaphylaxis after treatment with cetuximab, a monoclonal antibody that is produced by a non-primate mammalian cell line and used in cancer therapy [37, 38] .
Sialylation, α-1,3-galactosylation and ageing
Sialylation and α-1,3-galactosylation are both implicated in ageing. However, each of these processes has impact on ageing of the relevant elements in opposite ways. Biotechnological applications of sialylation could be beneficial for the pharmaceutical industry.
The terminal sialic acids on galactose residues protect serum glycoproteins and blood cells from degradation and, thus, are major determinants of their circulating half-life. Non-sialylated glycoproteins with free galactose residues are recognised by the liver asialo-glycoprotein receptors, which remove bound asialo-glycoproteins from the serum by endocytosis [42] . Because sialic acids are negatively charged, they potentially diminish the renal clearance of glycoproteins due to the repulsion of the glomerular membrane filter, which also increases the circulating half-life of glycoproteins [43] . Sias also influence the thermal stability, resistance to proteolytic degradation and solubility of proteins. Additionally, Sias inhibit the production of antibodies because they label proteins and cells as "self", preventing recognition by immune cell receptors [44] .
In modern medicine, numerous diseases are treated with therapeutic proteins. However, therapeutic proteins exhibit short circulating half-life due to their clearance from the bloodstream, instability, susceptibility to proteolysis and neutralisation by antibodies. For this reason, these drugs must be dosed frequently and in larger amounts, thus increasing the costs and risks of toxicity [45] . Because of the uniqueness of Sias, the sialylation of therapeutic glycoproteins may circumvent these challenges.
Sialylation has already been shown to be an effective tool for improving the properties of some therapeutic proteins. One example is darbepoetin alfa, which has been approved for sale in the U.S. [46] . Darbepoetin alfa is a hyperglycosylated human erythropoietin used for the treatment of anaemia and the reduction of its incidence. This protein was engineered to contain five N-linked carbohydrate chains; two more than the hyperglycosylated recombinant erythropoietin (rHuEPO). This increased sialic acid content gives darbepoetin alfa a threefold longer serum half-life and greater in vivo potency than rHuEPO, allowing it to be administered less frequently [47] . Flintegaard et al. [43] proved that N-glycans can prolong the in vivo circulation and enhance the pharmacodynamic effects of human growth hormone (GH), and Sias most likely play a crucial role in this effect. GH is cleared primarily by glomerular filtration and secondarily by receptormediated clearance. The synthetic addition of glycans to GH, which normally does not possess any N-glycans, can prolong its circulating half-life. In one study, two variants of GH that contained three N-glycans (3N-GH) differing in the extent of sialylation (58% versus 81%) were tested. Over a 4-day period, a single injection of either of these 3N-GH variants was more efficient than daily injections with wild-type GH [43] . A similar role of Sias in the reduction of glomerular filtration was also confirmed for the synthetic glycosylation of folliclestimulating hormone [48] .
Interesting results have been achieved for other proteins in addition to hormones. The human type I interferon alpha (hIFN-α) family contains inducible cytokines noted for their antiviral, antiproliferative and immunomodulatory effects. Recombinant hIFN-α2b is currently used for the treatment of hepatitis B and C and some types of cancer. This protein has low in vivo biological activity because of its short serum half-life and rapid clearance [49] . Ceaglio et al. [49] synthesized a long-acting recombinant hIFN-α2b by introducing four N-glycosylation sites (4N-IFN) . 4N-IFN showed increased resistance to serum protease inactivation and a 25-fold longer circulating half-life compared to recombinant hIFN-α2b. The circulating half-life of 4N-IFN was longer than that of the commercial pegylated derivative Intron-A PEG. These improvements are positive consequences of a high degree of terminal sialylation (10.6 mol of Sia per mole of 4N-IFN). The glycosylation also affected the activity. Whereas the in vitro antiviral and antiproliferative activity of 4N-IFN was decreased, its in vivo antitumour activity in animal models was enhanced [49] .
All of these mentioned sialylated therapeutic proteins were constructed by the mutation of amino acid residues to generate N-glycosylation sites (Asn-X-Thr/Ser) and produced by transformed Chinese hamster ovary cells so that the N-glycosylation occurred intracellularly. The disadvantage of this technique, however, is that the structures of the oligosaccharides attached to the glycoproteins produced in mammalian cell lines often vary, especially in the degree of sialylation, and the sialylation is often insufficient and incomplete. For the production of proteins with a defined sialoside structure, a more suitable option would be the in vitro remodelling of recombinant glycoproteins using the corresponding sialyltransferases. In vitro sialylation was successfully employed by Lindhout et al. [45] to test the influence of site-directed polysialylation on the properties of the therapeutic glycoprotein alpha-1-antitrypsin (A1AT). A1AT is the most prevalent serum serine protease inhibitor, and its deficiency can cause emphysema, chronic obstructive pulmonary disorder and other diseases. This glycoprotein contains three N-linked glycan sites that were polysialylated de novo using a two-step in vitro enzymatic modification procedure. First, the C. jejuni Cst-II (bifunctional α2,3/α2,8-ST) provided a primer for N-glycans (addition of 1 to 3 Neu5Ac), and the N. meningitides α2,8-polyST catalysed the polysialylation (addition of 4 to >70 Neu5Ac; 53% of the glycan chains were less than 20 Neu5Ac residues long). Short polysialic acid chains added to the existing glycan structure significantly prolonged the half-life of A1AT with no effect on its in vitro activity [45] . Pharmaceutical companies currently have additional polysialylated therapeutics in various stages of development [46] .
The biological stability of glycoproteins can also be modified by the biochemical engineering of the Sia side chain. Using this method, non-physiological N-acyl-modified sialic acids that are taken up by cells are incorporated into carbohydrate chains, where they replace 10-85% of the normal sialic acids [44] . It was shown that the replacement of Neu5Ac by a novel, engineered N-propanoylneuraminic acid resulted in a greater than 50% increase in the circulating halflife of highly sialylated CEACAM1, a member of the immunoglobulin superfamily [44, 50] .
Whereas sialic acids provide an anti-recognition signal for macrophages and hence, determine the maintenance of blood cells in circulation [51] , the α-gal epitope contributes to the removal of red blood cells from circulation. In the process of human red blood cell ageing, cryptic α-gal epitopes are exposed on the cell surface by the action of macrophage hydrolases [28, 51] . For this reason, a few hundred α-gal epitopes are present on the surface of normal senescent and sickle red blood cells (e.g., thalassemic cells) [28, 52] . Naturally occurring anti-Gal antibodies bind this epitope, enhancing the phagocytosis of red blood cells by reticuloendothelial macrophages and thus, their removal from circulation [28, 53] . Anti-Gal antibodies also interact with therapeutic recombinant glycoproteins that express α-gal, but no effect on their circulating halflife or activity has been shown [28] . However, in some individuals, the interaction of anti-Gal IgE with α-gal on therapeutic proteins (e.g., cetuximab) leads to an allergic reaction [37, 38] , as previously mentioned.
Sialylation, α-1,3-galactosylation and microorganisms
Sialylation and α-1,3-galactosylation are closely connected with microorganisms in many different ways.
Sias and the α-gal epitope (or α-gal-like epitopes) are (i) expressed on the host cell surface and act as receptors for certain pathogens or microbial toxins, (ii) they are expressed on the cell surfaces of some microorganisms and (iii) have the potential to be used in therapy.
Terminal sialic acids that decorate the surfaces of human cells serve as receptors for many pathogens, such as Helicobacter pylori, Plasmodium falciparum, the influenza virus and others [1, 54, 55] . The most prevalent Sia in humans is Neu5Ac, which is also recognised by CD33rSiglecs as belonging to the host. Due to convergent evolution, many human pathogens express Neu5Ac to engage CD33rSiglecs and, thus, inhibit the innate immune responses of the host (e.g., Streptococcus group B) [1, 56] . The expression of sialosides and/or some antigens similar to those present on the host cells is called "molecular mimicry" [56, 57] . Although these antigens are similar, they are distinct enough to induce an immune response, which also leads to the breakdown of tolerance to autoantigens. This finding suggests that "molecular mimicry" is a mechanism by which infectious agents may contribute to the development of autoimmune diseases [58] . The direct causes of autoimmune diseases remain unclear, but it is known that in addition to genetic factors, environmental triggers such as viruses, bacteria and other pathogens can participate in the development of autoimmune diseases [57] . Autoimmunity is also closely associated with inflammation, although the role of inflammation in the development of autoimmunity is still a subject of investigation [59] . In many autoimmune and infectious diseases (rheumatoid arthritis (RA), active Crohn's disease, tuberculosis, Lyme disease, sarcoidosis, etc.), an increased amount of low-galactosecontaining IgG antibodies (G0 glycoform), which have a pro-inflammatory effect, has been observed [60] .
The IgG molecule consists of two antigen-binding Fab arms that are connected to the effector-binding Fc region via a flexible hinge region. The Fc region has two interacting Ig domains and two domains that are separated by two oligosaccharide chains. These chains cover the hydrophobic faces and thus, prevent interactions between the domains. These oligosaccharides are heterogeneous (approximately 30 structures) and may be crucial for antibody function. Some residues of the sugar chains are conserved, while others are highly variable. Various glycoforms of IgG exist based on the attached oligosaccharides. The IgG G2 glycoform is the major form in normal IgG and is characterised by terminal galactose residues. The IgG G0 glycoform has terminal N-acetylglucosamine residues that bind the mannose-binding lectin and thus, activate inflammation. The IgG S2 glycoform, which contains two terminal sialic acid residues, has an antiinflammatory effect [9] . Sialylated IgG binds DC-SIGN, a receptor expressed on dendritic cells, which stimulates the production of IL-33 and leads to an increase in IL-4 + basophils. These cytokines modulate the expression of FcγRIIB (receptor) on the effector cells and thus, suppress inflammation [61] .
Intravenous immunoglobulin (IVIg) is used in the treatment of autoimmune diseases (e.g., rheumatoid arthritis, immune thrombocytopenia) due to its antiinflammatory properties. The small fraction of sialylated IgG that is present in the IVIg preparation is responsible for this activity. The α-2,6-linked Sias are necessary for this effect because the treatment of IVIg with α-2,6-sialidase eliminated its anti-inflammatory activity, whereas treatment with α-2,3-sialidase had no effect. On the other hand, IVIg-derived Fc fragments treated with β-1,4-galactosyltransferase to produce the G2 glycoform that were subsequently sialylated by α-2,6-ST to the fully sialylated form suppressed inflammation much more efficiently than the primary IVIg Fc fragments [62] . Anthony et al. [62] generated a recombinant IgG1 Fc that was sialylated in vitro by α-2,6-ST. This Fc displayed anti-inflammatory activity comparable to that obtained with in vitro α-2,6-sialylated IVIg-derived Fc fragments [62] . Glycoengineered IVIg or recombinant Fc fragments represent an improved alternative to the presently used therapeutic IVIg, leading to a decrease in the dose, the number of injections and the cost [62, 63] .
The α-gal epitope, which is expressed on the cells of mammals with the exception of humans, apes and Old World monkeys, also serves as a receptor for pathogens (e.g., Clostridium difficile enterotoxin A, bovine norovirus strain GIII) [64, 65] . α-gal or α-gal-like epitopes are also expressed on the surfaces of pathogens. These epitopes are immunogenic and induce anti-Gal antibody production. These antigenic α-gal epitopes interact strongly or weakly with the natural anti-Gal antibodies from healthy individuals. Enveloped viruses, such as the eastern equine encephalitis virus and the influenza virus, express the α-gal epitope when propagated in cells with active α1,3GalT. When these viruses are propagated in cells lacking α1,3GalT, the α-gal epitope is not expressed on their surface [66] . The α-gal epitope is also present on the cell surfaces of some protozoa (e.g., Trypanosoma cruzi, Leishmania) [66] and is carried by the extracellular vesicles of Paracoccidioides brasiliensis [67] . The α-gal epitope is commonly expressed on the cell surfaces of gastrointestinal bacteria (e.g., Klebsiella pneumoniae, Escherichia coli, Serratia marcescens), suggesting that this most likely provides the continuous antigenic stimulus for the production of natural anti-Gal antibodies in humans [66] .
The high abundance of natural anti-Gal antibodies may help to increase the immunogenicity of vaccines in humans. The immunogenicity of many microbial vaccines is very limited. Although the antigenic proteins are present, their uptake by antigen presenting cells (APCs), such as dendritic cells (DCs) and macrophages, is poor. This low uptake generally occurs because vaccinating proteins in solution or particulate vaccines lack recognition markers for APCs. For an efficient immune response, the vaccinating antigen must be recognised and internalised by APCs so that it can be transported to the regional draining lymph nodes for processing. Antigenic peptides are then presented on MHC class I and MHC class II that lead to the activation of CD8 + and CD4 + T cells, respectively. CD4 + T cells help B cells to produce the corresponding antibodies and also help activated CD8 + T cells to become cytotoxic T lymphocytes [68, 69] . The immunogenicity of vaccines is increased by administering them in the form of immune complexes with the relevant IgG antibody because the interaction of FcγR (receptor) on APCs with the Fc of the IgG molecule induces internalisation. It has been shown that many microbial vaccines (e.g., tetanus toxoid, hepatitis B envelope Ag, eastern equine encephalitis virus, trypanosome) show 10-to 1000-fold higher immunogenicity in complex with the corresponding IgG. However, there are two main problems associated with the use of these complexes as vaccines. The immune complexes must be formed in vitro, but the Fc regions of many monoclonal antibodies interact poorly with FcγR on APCs. Additionally, immunodominant epitopes may be masked by antibodies. A possibility to avoid these problems is to engineer a vaccine that expresses the α-gal epitope, allowing it to form complexes in vivo with the natural human anti-Gal antibodies [69] . This method is called α-gal HyperAcute ® Technology [70] . Abdel-Motal et al. [71] introduced a method to increase the immunogenicity of the gp120 envelope glycoprotein of the human immunodeficiency virus (HIV-1) vaccine. There are 13-16 biantennary carbohydrate chains on gp120, most of which are capped with sialic acid, that mask the virus from the immune system and thus, hinder the effective uptake of the vaccine. To improve vaccine efficacy, gp120 was glycoengineered in vitro by a two-step enzymatic reaction within one solution. The sialic acid located at the terminus of the carbohydrate chain was removed by neuraminidase to expose an N-acetyllactosamine residue (LacNAc). This LacNAc then served as an acceptor substrate for recombinant α1,3GalT. This recombinant α1,3GalT lacked the transmembrane and cytoplasmic domains, insuring its solubility without detergent. The enzymatic treatment converted >97% of the gp120 to gp120 αgal , which carried α-gal epitopes (~30 α-gal epitopes per molecule) instead of sialic acid. Immunisation with gp120 αgal led to the production of anti-gp120 antibodies in >100-fold higher titres and also induced a greater T-cell response compared to immunisation with wild-type gp120 [71] . Because HIV-1 gp120 has a high mutation rate and is therefore not particularly suitable for vaccines, Abdel-Motal et al. [72] proposed gp120 αgal as an effective platform for targeting other HIV-1 proteins to APCs. This type of vaccine would invoke the combined cellular immune response against a core or matrix virus protein (e.g., rev, p17 or p24) and both a cellular and humoral immune response against the envelope glycoprotein gp120. Their results show that immunisation with a vaccine containing the fused protein gp120 αgal /p24 induces the activation of a much higher number of T cells secreting IFNγ in response to p24 and also 10-to 30-fold higher cellular and humoral responses against gp120 than were observed after immunisation with gp120/p24 [72] .
Similar results were obtained for the influenza virus [68] . The inactivated virus was treated in vitro with recombinant α1,3GalT to synthesize α-gal epitopes. This method of α-gal synthesis was preferable to virus propagation in mammalian cells because capping with sialic acids leads to suboptimal intracellular synthesis. Using recombinant α1,3GalT in vitro, the expression of >3,000 α-gal epitopes per virion could be achieved. Immunisation with the enzymatically engineered virus led to much higher numbers of virus-specific CD8 + and CD4 + T cells and much higher antibody titres than the virus lacking α-gal was able to induce. The acceptor substrate for the enzyme was primarily LacNAc on the envelope glycoprotein hemagglutinin. For this reason, it was speculated that recombinant hemagglutinin expressing α-gal could substitute for vaccines containing inactivated influenza virus [68] .
The α-gal epitope is a safe and strong immunostimulatory and immunomodulatory agent in humans, making the α-gal HyperAcute ® Technology applicable for the improvement of any new or currently approved microbial vaccine [70] .
Sialylation, α-1,3-galactosylation and cancer
Immunotherapy is a popular field of cancer research because cancer vaccines are efficient and have limited toxicity [73] . Sialylation and α-1,3-galactosylation are promising tools for cancer immunotherapy. The sialic acid expression pattern changes in response to many pathological processes, including malignant transformation [7] . A typical feature of malignant human tumours is the increased expression of certain sialic acid-containing antigens [34] . Changes in Neu5Ac expression may protect tumour cells from the humoral and cellular defence systems. Neu5Ac molecules are also recognised by selectins on platelets, leukocytes and the endothelium and thus, facilitate metastasis [7] . In addition to changes in the presentation of Neu5Ac, tumour cells also accumulate large amounts of the non-human Neu5Gc that originates from digested food [7, 34] . Additionally, an immunomodulatory effect for Neu5Gc has been demonstrated because the ganglioside Neu5GcGM3 induces CD4 down-modulation on T cells [74] . As was previously suggested, antiNeu5Gc antibodies that are present in the circulation of patients can generate only a weak immune response that enhances leukocyte infiltration and angiogenesis, thus stimulating tumour growth. However, a high level of these antibodies could inhibit tumour growth [34] .
Normal cells express only a negligible amount of Neu5Gc, making this Sia a privileged target for cancer immunotherapy [10] . Several authors have described the successful use of anti-idiotypic monoclonal antibodies that mimic Neu5GcGM3 in immunotherapy for various types of cancer [73, 75, 76] . Mulens et al. [77] tested different types of vaccine in metastatic breast cancer patients. These vaccines consisted of the Neu5GcGM3 ganglioside extracted from mammalian erythrocytes bound to the outer membrane vesicles of N. meningitides in the form of very small sized proteoliposomes (VSSP) that were then mixed with adjuvant. The vaccine was immunogenic and well tolerated. The main antitumour effect was represented by the production of antibodies and the subsequent complement-mediated lysis and antibody-dependent cell-mediated cytotoxicity. The humoral response was specific, and hyperimmune sera from vaccinated patients inhibited CD4 down-modulation on T lymphocytes mediated by Neu5GcGM3. Two phase III clinical studies with this vaccine are in progress [77] .
A different approach to cancer immunotherapy is provided by the α-gal HyperAcute ® Technology [70] . In addition to Neu5Gc, there are many other tumourassociated antigens (TAAs) that are powerful targets for vaccination leading to tumour destruction. However, the TAAs for most types of cancer are unknown, and for sufficient immune response, it is necessary to include multiple TAAs. For these reasons, autologous [66] or allogenic tumours [78] may serve as the most suitable source of TAAs for vaccinations. The poor uptake of these tumour vaccines by APCs is a major obstacle to their use that might be solved by the expression of α-gal epitopes [66] . Glycoengineered cells must be irradiated to kill any live tumour cells, and then they can be injected into patients [13] . The mechanism of their immunostimulatory effect is the same as previously described for their application in microbial vaccines, and these vaccines also lead to humoral and cytotoxic immune responses.
Various methods for α-gal expression on these vaccine particles have been described [79] [80] [81] . The two most broadly used methods for α-gal expression are the transformation of tumour cells and enzymatic treatment.
Several authors have reported the increased efficiency of melanoma tumour vaccines genetically engineered to express the α-gal epitope [82] [83] [84] . Deguchi et al. [85] tested a vaccine composed of 50 Gy-irradiated PANC1 pancreatic cancer cells that were transfected to express the α-gal epitope. Vaccination with α-gal PANC1 led to a robust expansion of the B-cell and T-cell response to MUC1, the main antigen overexpressed in human pancreatic carcinoma. The antibodies produced were able to bind not only the MUC1 protein but also other unknown TAAs. The immune reaction was much stronger than that elicited by the parental PANC1. However, the authors also suggested that a tumour lysate that had been enzymatically engineered to express α-gal could be an effective material for pancreatic cancer vaccination because a tumour contains cancer stem cells in addition to differentiated cancer cells.
The enzymatic method proved to be highly efficient in α-gal epitope synthesis for tumour vaccines. Chen et al. [79] demonstrated the processing of leukaemia cells and the cell membranes of ovarian carcinoma by recombinant α1,3GalT. This enzyme, similar to the one used for microbial vaccines, was truncated and lacked the transmembrane and cytoplasmic domains. Optimal results were achieved by using neuraminidase to eliminate the terminal Sias and expose more LacNAc. LacNAc with or without terminal Sia is expressed on all normal and malignant human cells. Galactose was then attached to LacNAc in a second enzymatic reaction catalysed by recombinant α1,3GalT. Using this method, α-gal epitopes were successfully introduced onto large numbers of leukaemia cells (6x10 6 α-gal epitopes per cell) and onto ovarian carcinoma cell membranes [79] . Recombinant α1,3GalT is recommended for the synthesis of α-gal epitopes on tumour cells or cell membranes as required for the preparation of tumour vaccines [79, 86] .
An alternative to tumour vaccines is the direct intratumoural injection of α-gal glycolipids. The injected glycolipids insert spontaneously into tumour cell membranes, exposing the α-gal epitopes on the tumour cell surfaces. The subsequent binding of anti-Gal antibodies leads to local inflammation and the activation of complement, which results in the xenograft-like destruction of the tumour. Simultaneously, α-gal epitopes provide a label for the uptake of these cells by APCs and thus, convert lesions into endogenous vaccines, which prevents metastases from developing into lethal lesions. The efficiency of this method was demonstrated for melanoma lesions [87, 88] , and glycolipids containing α-gal were obtained from the membranes of rabbit red blood cells [87] . The α-gal epitope could also be installed via the in vitro glycosylation of lipids using recombinant α1,3GalT to avoid the isolation of these glycolipids from mammalian cells.
Thus far, the use of the α-gal HyperAcute ® Technology in cancer vaccines has been shown to be safe in human clinical trials [70] .
Synthesis of sialosides and the α-gal epitope
Over the past several years, as the biological impact of oligosaccharides and glycoconjugates has become clear, the demand for effective strategies for oligosaccharide synthesis has rapidly increased [89] . As previously mentioned, the sialylation and α-1,3-galactosylation of the glycoproteins produced by mammalian cell lines is often inconsistent and insufficient. For this reason, there is a need for effective in vitro glycosylation strategies. One possibility is chemical synthesis, which requires multiple reaction steps and also faces difficulties associated with branched oligosaccharide synthesis and with generating the correct regio-and stereochemistry of the synthesized glycosidic bond [89] .
An alternative to chemical synthesis is enzymatic synthesis, which occurs regio-and stereoselectively under mild conditions without the need for protecting group manipulation [89] . Within enzymatic synthesis, there are whole-cell approaches. Kyowa Hakko, Inc. (1998) developed a method that combines various engineered microbial strains for the production of the donor substrate, acceptor substrate and final enzyme for oligosaccharide synthesis. Using this method, the large-scale production of UDP-Gal, CMP-Neu5Ac and related oligosaccharides has been achieved [90] . The Samain group [91] developed a living factory approach. This approach uses a single bacterial metabolic mutant strain. The carbohydrate biosynthetic pathways were engineered by deleting certain degradation enzymes and incorporating specific glycosyltransferases, transporters, sugar nucleotide-producing enzymes and other carbohydrate decorating enzymes. Cells engineered in this fashion can be used to produce carbohydrate chains once provided with the exogenous donor and acceptor substrates. The donor is activated by engineered metabolic pathways in the cell. However, the scale of substrates is restricted because they have to be taken up by cells [90, 91] . This method has been applied for the production of 3'-sialyllactose [92] as well as the α-gal epitope [93] . The Wang group introduced a "superbug" for α-gal epitope synthesis, i.e., a metabolically engineered E. coli strain containing a plasmid that harbours a gene cluster encoding all enzymes in the biosynthetic pathway [94] . The main advantage of these whole-cell methods is the utilisation of the microorganisms' own metabolic pathways for synthesis from inexpensive materials without the addition of nucleotides or the need for complicated enzyme purification [90] .
The most effective method for oligosaccharide production is chemoenzymatic synthesis. This method represents a combination of the flexible chemical method and the highly efficient regio-and stereoselective enzymatic synthesis for the generation of naturally occurring and non-natural oligosaccharides with great diversity. This type of synthesis usually consists of the chemical or chemoenzymatic production of glycosyltransferase acceptors and sugar (donor) derivatives or precursors followed by the enzymatic synthesis of oligosaccharides. In some cases, oligosaccharides are synthesised enzymatically that are then used to produce more complex sugar chains via chemical synthesis [90] . A one-pot multi-enzyme approach has also been employed for the production of the α-gal epitope [95] and sialosides with diverse sialic acid forms and various sialyl linkages without requiring the purification of intermediates [96] . However, for functional studies, these various sialosides must be individually purified. To avoid the purification step, a combinatorial chemoenzymatic approach has been developed that includes high-throughput screening without product purification [97] .
An advantageous model for in vitro glycosylation could be provided by the linkage of two reactions, such as a polyphosphate kinase using polyphosphate to generate energy-rich nucleoside phosphates that activate the donor substrates of the corresponding glycosyltransferases [98] , e.g., sialyltransferases for sialylation or α-1,3-galactosyltransferase for the synthesis of the α-gal epitope.
Sialyltransferases
Sialyltransferases (STs) are enzymes that play a crucial role in the biosynthesis of sialosides (sialic acidcontaining oligosaccharides) and sialoglycoconjugates (sialic acid-containing glycoconjugates). These enzymes catalyse the transfer of Sia (Neu5Ac or another derivative of sialic acid) from its activated sugar nucleotide donor, CMP-sialic acid, to an acceptor [90] . They govern addition of Sia with α-2,3-or α-2,6-linkage to the terminal galactose, with α-2,6-linkage to the terminal GalNAc or with α-2,8-linkage to the terminal Sias [99] .
Sias are synthesised in deuterostome organisms and some bacteria. The physiological precursor of all sialic acids is N-acetyl-d-mannosamine (ManNAc). ManNAc is formed from UDP-N-acetylglucosamine (UDP-GlcNAc) by UDP-N-acetylglucosamine 2-epimerase. In mammals, this enzyme is bifunctional and also catalyses the phosphorylation of ManNAc to ManNAc-6-phosphate. Following this reaction, ManNAc-6-phosphate is condensed with phosphoenolpyruvate to produce Neu5Ac-9-phosphate, which is then dephosphorylated to give Neu5Ac. The biosynthesis is simpler in bacteria because ManNAc can be directly condensed with phosphoenolpyruvate to give Neu5Ac. The resulting primary Neu5Ac is either modified to another type of Sia or activated in the nucleus by CMP-Neu5Ac synthetase to produce CMPNeu5Ac [44, 100] . CMP-Neu5Ac acts as a feedback inhibitor of the epimerase activity of the key enzyme UDP-N-acetylglucosamine 2-epimerase [44] . The modifications of Neu5Ac are most likely the result of evolutionary selection [90] because some of them modulate the affinity of these monosaccharides for mammalian and microbial receptors and can also hinder apoptosis (e.g., O-acetylation) [2] . The amino acid group can be acetylated, glycosylated or replaced by a hydroxyl group. The hydroxyl groups of Sias can be singly or multiply acetylated at O4, O7, O8 or O9 and are often methylated or modified by acetate, lactate, phosphate or sulphate esters. Of all types of Sias, only Neu5Ac is ubiquitous [5] .
STs are metal ion-independent inverting enzymes, which means that a monosaccharide β-linked to its donor (CMP-Sia) is α-linked in the final product. These enzymes follow an S N 2-like single displacement mechanism. This mechanism consists of the nucleophilic attack of the OH group of the acceptor onto the anomeric centre of the donor sugar. The reactive oxygen of the acceptor is then deprotonated by a catalytic residue that serves as a general base. The reaction also involves the formation of an oxocarbenium ion transition state and the simultaneous departure of the nucleotide leaving group [101, 102] .
All known STs are Golgi type II transmembrane glycosyltransferases [102, 103] that share a typical architecture. These proteins consist of a short N-terminal cytoplasmic tail, a single transmembrane domain, a stem region of variable length and a large C-terminal catalytic domain facing the luminal side [90, 102] . They are members of five CAZy glycosyltransferase (GT) families (CAZy = Carbohydrate Active enZYme database, www.cazy.org). Mammalian STs and viral STs belong to the GT29 family, while bacterial STs are members of four different CAZy families: GT38, GT42, GT52 and GT80 [90] .
Bacterial STs have been identified thus far in the genera Neisseria, Escherichia, Campylobacter, Haemophilus, Pasteurella, Photobacterium, Vibrio and Streptococcus [102, 104] . The STs of prokaryotes are not directly related to the eukaryotic STs [103] . Compared to the eukaryotic enzymes, bacterial STs have a more flexible substrate specificity [102] and are therefore, more suitable for biotechnological applications [90] .
α-1,3-galactosyltransferase
α-1,3-galactosyltransferase (α1,3GalT) governs the transfer of galactose (Gal) from UDP-Gal (activated sugar nucleotide donor) to acceptors on glycoproteins and glycolipids with non-reducing terminal disaccharides, catalyzing the formation of an α-1,3-glycosidic bond. The synthesis of the α-gal epitope requires a type 2 disaccharide LacNAc as an acceptor, but α1,3GalT tolerates modified versions of this disaccharide as acceptors to synthesize compounds that are able to bind anti-Gal antibodies [105] .
α1,3GalT belongs to the class of retaining glycosyltransferases, which means that a Gal that is α-linked to its donor is also α-linked in the final product [106] . Our knowledge of the reaction mechanisms of retaining glycosyltransferases is still limited. Zhang et al. [106] believe that α1,3GalT acts through a sequential mechanism in which the metal cofactor, donor and acceptor bind to the enzyme prior to catalysis and that UDP is not released before the transfer of Gal to an acceptor. In contrast to sialyltransferases, α1,3GalT is a metal ion-dependent enzyme. The catalytic domain of the enzyme is activated by Mn 2+ , but its affinity for this ion is very low relative to physiological levels. Zn 2+ is more likely to be the natural cofactor because it induces higher levels of activity at physiological metal ion concentrations [106] . Boix et al. [107] suggested that a divalent cation (Mn 2+ ) is required for donor substrate binding and that UDP is required for acceptor substrate binding, indicating that the donor and the acceptor bind to the enzyme in an obligatory ordered manner.
According to the CAZy database, α1,3GalT is a member of the GT6 family. It is a Golgi type II transmembrane GT, which indicates that it consists of a short N-terminal cytoplasmic tail linked to a single transmembrane domain that is followed by a stem region connected to a luminal C-terminal catalytic domain [108] .
Conclusions
The glycan chains decorating the surfaces of cells are structurally and functionally variable. Interestingly, the presence or absence of some oligosaccharide chains can be species specific. N-glycolylneuraminic acid and α-1,3-galactose are two sugars that have been eliminated during human evolution. Subsequently, humans have produced antibodies to these sugars that may cause complications associated with the consumption of foods of mammalian tissues. However, the elimination of these sugars has also brought some benefits for preventive and curative medicine.
N-glycolylneuraminic acid of dietary origin is almost absent from normal human tissues, but it is abundantly expressed on cancer cells. A high level of anti-N-glycolylneuraminic acid antibodies has an antitumour effect, which makes N-glycolylneuraminic acid a privileged target for cancer immunotherapy. In the case of the α-gal epitope, humans have a naturally high titre of circulating anti-Gal antibodies. Microbial or cancer vaccines, which contain the corresponding oligosaccharide chains. There are various methods for the in vitro synthesis of oligosaccharides. Because of their higher efficiency and lower risk of toxicity, chemoenzymatic methods are often preferred to wholecell approaches. Low cost is required in addition to efficiency. The expense of synthesizing these materials could be reduced by the linkage of the synthesis with the production of energy-rich nucleoside phosphates for sugar donor activation. The development of low-cost, high-efficiency methods for oligosaccharide synthesis is necessary for their practical applications.
antigens expressing the α-gal epitope, form in vivo complexes with anti-Gal antibodies. This complex formation increases their immunogenicity. In addition to medical applications, cryptic α-gal epitopes appear naturally on senescent and sickle red blood cells. The subsequent binding of anti-Gal antibodies contributes to the removal of these red blood cells from circulation. Sialic acids have the opposite effect, as their presence prevents the clearance of blood cells.
Sugar molecules also affect the properties of single proteins. Because sialic acids determine the circulation half-life of glycoproteins, the sialylation of therapeutic proteins improves their potency and hence, reduces the necessary dosage. The sialylation of IgG antibodies has medical applications as well because the sialylated forms of IgG antibodies have an anti-inflammatory effect. These antibodies can be used in the treatment of inflammatory diseases, particularly autoimmune diseases.
Sialylation and α-1,3-galactosylation have a high potential for medical applications. For this reason, there is a need for the effective synthesis of the corresponding
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